<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02673697</url>
  </required_header>
  <id_info>
    <org_study_id>TPS003</org_study_id>
    <nct_id>NCT02673697</nct_id>
  </id_info>
  <brief_title>Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement</brief_title>
  <acronym>PERSIST-AVR</acronym>
  <official_title>Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement A Controlled Randomized Trial in the Surgical Treatment of Aortic Valve Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LivaNova</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LivaNova</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized, stratified non blinded multi-center, international, post market
      trial assessed in a non-inferiority study.

      A minimum of 1234 subjects will be enrolled at approximately 60 worldwide investigational
      sites where the device is commercially available.

      The primary objective of this trial is to test the safety and efficacy of Perceval versus
      standard sutured stented bioprosthetic aortic valves among the intended trial population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PERSIST-AVR is designed to collect data on sutureless valve (Perceval sutureless aortic heart
      valve), a new type of biological aortic valve, comparing data with standard biological aortic
      valve, considered the gold standard for aortic valve replacement. This prospective,
      randomized international multicenter study is planned to demonstrate, as primary endpoint,
      the non inferiority of Major Adverse Cardiac and Cerebrovascular (MACCE) events at one year
      while showing superiority in resource consumptions at hospital discharge in patients treated
      with Perceval valve when compared to standard aortic valve replacement. The study is planned
      to cover the lack of prospective, randomized comparison data between sutureless valve and
      standard aortic biological sutured valve. To achieve the primary endpoint, 1234 patients will
      be recruited in 60 worldwide investigational sites. The be part of the trial, investigational
      sites should have demonstrated experience with the implantation of the Perceval and able to
      implement the requirements of the study protocol.. All subjects with severe symptomatic
      aortic stenosis or steno-insufficiency who are candidates for surgical replacement of their
      native aortic valve according to established guidelines in current medical practice and as
      specified in the Perceval valve Instruction for Use (IFU) are the intended population for
      inclusion in this randomized trial. The patients will be followed for 5 years after the
      implant, the total duration of study including the enrollment time will be 7 years
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from MACCE</measure>
    <time_frame>1 year post-operatively</time_frame>
    <description>The primary endpoint is freedom from MACCE (composite endpoint of all cause death, myocardial infarction, stroke, and valve re-intervention) at one year based on Clinical Event Committee (CEC) adjudication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgical times</measure>
    <time_frame>Intra-operative</time_frame>
    <description>Cross clamp time during index procedure
Cardiopulmonary bypass time during index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalized Consumption Index</measure>
    <time_frame>Hospital Discharge (average 10 days)</time_frame>
    <description>Normalized Consumption Index including resource consumption items such as (but not limited to):
Operative room time,
Duration of ICU and total hospital stay
Incidence of specific serious adverse events as defined in Appendix 3
Blood transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduced Normalized Consumption Index</measure>
    <time_frame>Hospital Discharge (average 10 days)</time_frame>
    <description>Reduced Normalized Consumption Index, including resource consumption items such as (but not limited to):
Operative room time,
Duration of ICU and total hospital stay
Incidence of specific serious adverse events as defined in Appendix 3
Blood transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire</measure>
    <time_frame>At 1 month and 1 year post surgery</time_frame>
    <description>Questionnaire for quality of life (EQ5D)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraprocedural and periprocedural serious adverse events regardless of relationship with the device</measure>
    <time_frame>72 hours post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All valve and procedure relevant serious adverse events as specified in Valve Academic Research Consortium-2 (VARC-2) guidelines</measure>
    <time_frame>At 30 days and annually up to 5 years post surgery</time_frame>
    <description>Early safety at 30 days
Clinical efficacy after 30 days
Time related valve safety: [Structural Valve Deterioration (SVD), endocarditis, Thrombosis, Thromboembolic events (excluding stroke), and bleeding] annually up to 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious device related adverse events</measure>
    <time_frame>Up to 5 years post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from MACCE</measure>
    <time_frame>At 2, 3, 4 and 5 years post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Pacemaker implantation</measure>
    <time_frame>Up to 1 year post surgery</time_frame>
    <description>The rate of pacemaker implantation during the first year post surgery will be analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic endpoints (site-reported data)</measure>
    <time_frame>Preoperatively, at hospital discharge (average 10 days), between 1-3 month, 1 year, 3 year and 5 years post surgery</time_frame>
    <description>Performance of the valve in terms of hemodynamic behavior</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic endpoints in a reduced cohort of patients assessed by core lab</measure>
    <time_frame>Preoperatively, at hospital discharge (average 10 days), between 1-3 month, 1 year, 3 year and 5 years post surgery</time_frame>
    <description>Performance of the valve in terms of hemodynamic behavior.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1234</enrollment>
  <condition>Aortic Valve Disease</condition>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Perceval</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Perceval sutureless aortic heart valve (Perceval valve) is a bioprosthesis manufactured with bovine pericardium and assembled on a Nitinol stent. The Perceval valve is designed to offer an alternative to surgically implanted flexible prostheses (stented and stentless biological valves). A special feature of the device is that it is self-anchoring and does not require sutures to be fixed to the implant site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>other Stented biological valves</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The comparator will be other commercially approved standard biological sutured stented valves, both bovine and porcine. The choice of the comparator tissue valve will be at the discretion of the participating investigators.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Perceval valve</intervention_name>
    <description>Sutureless Aortic Biological Valve</description>
    <arm_group_label>Perceval</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>other stented biological valve</intervention_name>
    <description>Any biological stented valves available on the market (Edwards, Medtronic, St.Jude, LivaNova, Labcor)</description>
    <arm_group_label>other Stented biological valves</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject has an indication for treatment by valve replacement with a bioprosthesis
             according to the IFU, through either full sternotomy or mini-sternotomy.

          2. The subject has aortic valve disease that can be treated with a commercially available
             Perceval valve size, based on preoperative CT-scan.

          3. The subject has:

               1. critical aortic valve area defined as an initial aortic valve area of ≤1.0 cm2 or
                  aortic valve area index &lt; 0.6 cm2/m2 AND

               2. Mean gradient &gt; 40 mmHg or Vmax &gt; 4 m/sec by resting echocardiogram or
                  simultaneous pressure recordings at cardiac catheterization [or with dobutamine
                  stress, if subject has a left ventricular ejection fraction (LVEF) &lt;55%] or
                  velocity ratio &lt; 0.25;

          4. The subject is symptomatic due to aortic stenosis with functional class of New York
             Heart Association (NYHA) II or higher.

          5. The subject has signed the informed consent.

          6. The subject is of legal minimum age.

          7. The subject will be available for postoperative follow-up beyond one year.

        Exclusion Criteria:

          1. The subject has a contraindication for treatment by the Perceval valve or by a
             bioprosthetic aortic valve as stated in the IFU.

          2. The subject has aneurismal dilation or dissection of the ascending aortic wall.

          3. The subject is scheduled for concomitant procedures other than Coronary Aortic Bypass
             Graft (CABG), myectomy with or without aortic annulus enlargement

          4. The subject has congenital bicuspid (i.e. Sievers type 0) or unicuspid aortic valve.

          5. Anatomical structures not suitable for Perceval valve such as: aortic root
             enlargement, where the ratio between the diameter of the sino-tubular junction and the
             annulus diameter is &gt; 1.3.

          6. The subject has a prosthetic heart valve in any position, including mitral valve
             repair.

          7. The subject has a stroke or myocardial infarction (STEMI and NSTEMI) within 30 days
             prior to the planned valve implant surgery.

          8. The subject has active endocarditis, myocarditis, or sepsis.

          9. The subject is in cardiogenic shock manifested by low cardiac output and needing
             hemodynamic support.

         10. The subject is allergic to nickel alloys.

         11. The subject is already included in another clinical trial that could confound the
             results of this clinical investigation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theodor Fischlein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Nurnberg, Nurnberg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Lorusso, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MUMC+, Maastricht, the Netherlands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michele Nozza</last_name>
    <phone>0039 346 744 1132</phone>
    <email>michele.nozza@livanova.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Royal Melbourn</name>
      <address>
        <city>Parkville VIC</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alistair Royse</last_name>
      <email>Alistair.Royse@unimelb.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinische Abteilung fuer Herzchirurgie</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Otto Dapunt</last_name>
      <email>Otto.Dapunt@klinikum-graz.at</email>
    </contact>
    <contact_backup>
      <last_name>Manuela Zederbauer</last_name>
      <email>manuela.zederbauer@medunigraz.at</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Hietzing</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Grabenwoeger</last_name>
      <email>Martin.Grabenwoeger@wienkav.at</email>
    </contact>
    <contact_backup>
      <last_name>Zsuzsanna Arnold</last_name>
      <email>zsuzsanna.arnold@wienkav.at</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Antwerp</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dina de Bock</last_name>
      <email>dina.de.bock@uza.be</email>
    </contact>
    <contact_backup>
      <last_name>Nathalie Brosens</last_name>
      <email>nathalie.brosens@uza.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cliniques Univ. Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent DE KERCHOVE</last_name>
      <email>laurent.dekerchove@uclouvain.be</email>
    </contact>
    <contact_backup>
      <last_name>Fadoua KADDOURI</last_name>
      <email>fadoua.kaddouri@uclouvain.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filip Rega</last_name>
      <email>filip.rega@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Klaartje Van den Bossche</last_name>
      <email>klaartje.vandenbossche@uzleuven.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>2H234</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shaohua Wang</last_name>
      <email>Shaohua.Wang@albertahealthservices.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southlake Regional Health Centre</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kevin Teoh</last_name>
      <email>KTeoh@southlakeregional.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis Bouchard</last_name>
      <email>andre.denis.bouchard@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Voisine</last_name>
      <email>pierre.voisine@fmed.ulaval.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frederic Pinaud</last_name>
      <email>frederic.pinaud@me.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>C.H.U. de Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sidney Chocron</last_name>
      <email>sidney.chocron@univ-fcomte.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital privé de Bois Bernard</name>
      <address>
        <city>Bois Bernard</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier Fabre</last_name>
      <email>ofabre@ch-lens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard Albat</last_name>
      <email>b-albat@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>C.H.U. de Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Folliguet</last_name>
      <email>t.folliguet@chu-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Corbi</last_name>
      <email>p.corbi@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Siepe</last_name>
      <email>matthias.siepe@universitaets-herzzentrum.de</email>
    </contact>
    <contact_backup>
      <last_name>Gabriele Lechner</last_name>
      <email>gabriele.lechner@universitaets-herzzentrum.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Herz- und Gefäß-Klinik</name>
      <address>
        <city>Bad Neustadt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aris Lenos</last_name>
      <email>Aris.Lenos@herzchirurgie.de</email>
    </contact>
    <contact_backup>
      <last_name>Monika Back</last_name>
      <email>Monika.Back@herzchirurgie.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Dresden GmbH Universitätsklinik</name>
      <address>
        <city>Dresden</city>
        <zip>1307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Utze Kappert</last_name>
      <phone>+49 351 450 1808</phone>
      <email>utz.kappert@herzzentrum-dresden.com</email>
    </contact>
    <contact_backup>
      <last_name>Katrin Plötze</last_name>
      <email>Katrin.Ploetze@herzzentrum-dresden.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>ASKLEPIOS Klinikum Harburg</name>
      <address>
        <city>Hamburg</city>
        <zip>D- 21075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thorsten Hanke</last_name>
      <email>t.hanke@asklepios.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Heart Center Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evaldas Girdauskas</last_name>
      <phone>+49 40 7410 52440</phone>
      <email>e.girdauskas@uke.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malakh Shrestha</last_name>
      <email>Shrestha.Malakh.lal@mh-hannover.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg</name>
      <address>
        <city>Nürnberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steffen Pfeiffer</last_name>
      <email>Steffen.Pfeiffer@klinikum-nuernberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Fatima Jiven-Jetzelsberger</last_name>
      <email>Fatima.Jiven-Jetzelsberger@klinikum-nuernberg.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Gottsegen Hungarian Institute os Cardiology</name>
      <address>
        <city>Budapest</city>
        <zip>H-1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laszlo Szekely</last_name>
      <email>lszekely@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dani Bitran</last_name>
      <email>bitrand@szmc.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheba medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ehud Raanani</last_name>
      <email>Ehud.Raanani@sheba.health.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Poliambulanza Istituto Ospedaliero</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Troise</last_name>
      <email>giovanni.troise@poliambulanza.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Cuore Morgagni Pedara</name>
      <address>
        <city>Pedara</city>
        <state>CT</state>
        <zip>95030</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmelo Mignosa</last_name>
      <email>carmignosa@tiscali.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Moriggia</last_name>
      <email>moriggia.stefano@hsr.it</email>
    </contact>
    <contact_backup>
      <last_name>Davide Schiavi</last_name>
      <email>schiavi.davide@hsr.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>lstituto Clinico Sant'Ambrogio e San Siro</name>
      <address>
        <city>Milan</city>
        <state>MI</state>
        <zip>20149</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mattia Glauber</last_name>
      <email>mattia.glauber@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Toscana Gabriele Monasterio-Presidio Ospedaliero di Massa</name>
      <address>
        <city>Massa</city>
        <state>MS</state>
        <zip>54100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Solinas</last_name>
      <email>marco.solinas@ftgm.it</email>
    </contact>
    <contact_backup>
      <last_name>Alessandra Parlanti</last_name>
      <email>parlantialessandra@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Muneretto</last_name>
      <email>claudiomuneretto@icloud.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale SS. Annunziata</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabriele Di Giammarco</last_name>
      <email>gabriele.digiammarco@unich.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Carlo Poma</name>
      <address>
        <city>Mantova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manfredo Rambaldini</last_name>
      <email>manfredo.rambaldini@aopoma.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erwin Tan</last_name>
      <email>erwin.tan@catharinaziekenhuis.nl</email>
    </contact>
    <contact_backup>
      <last_name>Esther van Dooren-Putmans</last_name>
      <email>esther.v.dooren@catharinaziekenhuis.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Maastricht University Hospital</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Kats</last_name>
      <email>suzanne.kats@mumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polisano European Hospital</name>
      <address>
        <city>Sibiu</city>
        <zip>550172</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Victor Costache</last_name>
      <email>victorscostache@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario De A Coruña</name>
      <address>
        <city>A Coruna</city>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Cuenca Castillo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital University Germans Trias I Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Ruyra-Baliarda</last_name>
      <email>xruyra.germanstrias@gencat.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Virgen De La Arrixaca</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sergio Cánovas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ankara University Cebeci Education and Research Hospitals</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ahmet Rüçhan Akar</last_name>
      <email>akarruchan@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marmara University</name>
      <address>
        <city>Istanbul</city>
        <zip>34722</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>C. Selim Isbir</last_name>
      <email>selim.isbir@marmara.edu.tr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Victoria Hospital</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antony Walker</last_name>
      <email>Antony.Walker@bfwhospitals.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Amanda Finch</last_name>
      <email>Amanda.Finch@bfwhospitals.nhs.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2016</study_first_submitted>
  <study_first_submitted_qc>February 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2016</study_first_posted>
  <last_update_submitted>April 11, 2017</last_update_submitted>
  <last_update_submitted_qc>April 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sutureless valve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

